Semax Research Peptide: What Preclinical Studies Reveal About This Synthetic ACTH Analogue
Published by the Elite Biologix Research Team — Compiled by clinical pharmacists with 27+ years of sterile compounding experience. Independent research compilation for scientific and educational reference only.
Key Takeaways
- Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of ACTH(4-7) with a Pro-Gly-Pro C-terminal extension that significantly prolongs its membrane half-life in rodent tissue preparations compared to native ACTH fragments (Dolotov et al., Bioorg Khim, 2004, PMID: 15344653).
- A single intranasal dose (50 µg/kg) elevated BDNF protein ~1.4-fold and exon III BDNF mRNA ~3-fold in rat hippocampus within hours in controlled rodent studies (Dolotov et al., Brain Research, 2006, PMID: 16996037).
- Transcriptome analysis in transient MCAO rat models identified 394 Semax-responsive genes at 24 hours, with 312 directly opposing the ischemia-reperfusion gene expression pattern (Filippenkov et al., Genes (Basel), 2020, PMID: 32580520).
- As of 2026, Semax remains a research compound. All available data originates from in vitro assays and animal models — no approved human indications exist outside of limited Russian clinical registrations.
Among the synthetic neuropeptide analogues studied in preclinical neuroscience, Semax occupies a distinctive position: it is one of the few research peptides supported by a substantial body of peer-reviewed mechanistic data from a single coordinated research program. Originating from the Institute of Molecular Genetics of the Russian Academy of Sciences, the Semax research literature spans pharmacokinetics, receptor binding kinetics, neurotrophin signaling, ischemia neuroprotection models, and transcriptome-level gene expression analysis.
This article reviews the published preclinical literature on Semax — what the data actually shows, what the methodological strengths and limitations are, and why this heptapeptide has remained a subject of sustained scientific interest for researchers studying neurotrophin signaling and neuroprotection.
What Is Semax? Structural Composition and Pharmacokinetic Profile
Semax binds to specific high-affinity sites in rat basal forebrain plasma membranes with a dissociation constant (Kd) of 2.41 ± 1.02 nM and a maximal binding capacity (Bmax) of 33.5 ± 7.9 fmol/mg protein, and its membrane-level half-life in those preparations exceeds one hour — compared to approximately 2–5 minutes for native ACTH(4-10) (Dolotov et al., Bioorg Khim, 2004, PMID: 15344653). That extended stability is a direct consequence of the Pro-Gly-Pro C-terminal addition, which blocks dipeptidylaminopeptidase cleavage at the Phe-Pro bond present in the native ACTH fragment.
Semax's full sequence — Met-Glu-His-Phe-Pro-Gly-Pro — places it in the melanocortin neuropeptide family. Its core ACTH(4-7) sequence (His-Phe-Arg-Trp in the native hormone; Met-Glu-His-Phe in Semax) interacts with melanocortin receptors, particularly MC4R, which is densely expressed in limbic and cortical regions of the rodent brain. The Pro-Gly-Pro tripeptide metabolite that forms during Semax degradation retains biological activity, making Semax function as a dual compound in preclinical systems.
Intranasal pharmacokinetic studies in rodents showed that 0.093% of total radioactivity per gram was detectable in brain tissue at two minutes post-administration, with approximately 80% of that signal representing intact, unmetabolized Semax (Shevchenko et al., Bioorg Khim, 2006, PMID: 16523722). This rapid CNS penetration following intranasal delivery is a key design advantage in rodent experimental protocols, where researchers require predictable brain exposure without systemic injection.
Research note: The Pro-Gly-Pro tripeptide that Semax releases upon partial degradation is itself a naturally occurring neuropeptide found in the central nervous system. This creates an unusual pharmacological scenario: the parent compound and its primary metabolite may act through overlapping but non-identical receptor populations. Preclinical studies that attribute Semax effects solely to the parent heptapeptide may underestimate the contribution of PGP metabolite activity. Future mechanistic research distinguishing these contributions would strengthen the interpretability of existing data.View our Semax research compound.
BDNF and TrkB Signaling: The Neurotrophin Induction Evidence
In 2006, Dolotov and colleagues published results showing that a single intranasal administration of Semax at 50 µg/kg elevated BDNF protein levels approximately 1.4-fold in rat hippocampus, increased exon III BDNF mRNA 3-fold, and raised TrkB receptor mRNA 2-fold — with TrkB tyrosine phosphorylation (the activation marker for the receptor's kinase domain) elevated 1.6-fold at the same timepoint (Dolotov et al., Brain Research, 2006, PMID: 16996037). These findings in rat hippocampal tissue placed Semax among a small group of compounds capable of activating the full BDNF-TrkB signaling cascade with a single dose.
A companion study by the same group confirmed that BDNF protein elevation from Semax was anatomically specific — detectable in basal forebrain but not cerebellum — consistent with the regional distribution of MC4R expression in the rodent brain (Dolotov et al., Journal of Neurochemistry, 2006, PMID: 16635254). This specificity distinguishes Semax's neurotrophin effects from broad, non-selective BDNF inducers and adds mechanistic precision to its preclinical profile.
Molecular Marker Change vs. Control Tissue / Timepoint BDNF protein +1.4-fold Rat hippocampus, 3 h post-dose Exon III BDNF mRNA +3.0-fold Rat hippocampus, 3 h post-dose TrkB mRNA +2.0-fold Rat hippocampus, 3 h post-dose TrkB phosphorylation (activation) +1.6-fold Rat hippocampus, 3 h post-dose BDNF protein (basal forebrain) Elevated (region-specific) Not detected in cerebellum — anatomically selective Source: Dolotov et al., Brain Research, 2006 (PMID: 16996037) and Journal of Neurochemistry, 2006 (PMID: 16635254). Single intranasal dose, 50 µg/kg, Wistar rats. The downstream consequences of TrkB phosphorylation in the rodent brain include activation of MAPK/ERK signaling (associated with synaptic plasticity and long-term potentiation markers in animal models) and PI3K/Akt pathways (associated with neuronal survival in stress paradigms). Whether these cascades are meaningfully activated by Semax's BDNF induction in rodent models remains an open research question — the published data establishes receptor activation but does not quantify downstream effector changes.
A 2009 study by Glazova and colleagues extended the temporal and anatomical analysis, finding that Semax produced multidirectional, time-dependent neurotrophin induction patterns across hippocampus, frontal cortex, and retina in rats — with BDNF significantly increased at 90 minutes post-dose in retinal tissue (Glazova et al., Journal of Molecular Neuroscience, 2009, PMID: 19662538). The non-uniform temporal pattern across regions suggests that Semax's neurotrophin effects are not a simple bulk induction but a regionally choreographed response — a mechanistic distinction relevant to researchers designing region-specific studies.
Ischemia Neuroprotection: Rodent MCAO Model Research
Preclinical ischemia research represents the most mechanistically detailed area of the Semax literature. In permanent middle cerebral artery occlusion (pMCAO) rat models, Semax selectively enhanced BDNF transcription at 3 hours post-occlusion and NGF and NT-3 transcription at 24–72 hours, while the comparison peptide Pro-Gly-Pro produced non-selective, broader neurotrophin induction without the same temporal precision (Dmitrieva et al., Cell and Molecular Neurobiology, 2010, PMID: 19633950). This specificity is mechanistically significant: it suggests Semax acts on discrete regulatory elements within the neurotrophin gene network rather than producing blanket transcriptional activation.
The strongest mechanistic evidence comes from a 2020 transcriptome-level study by Filippenkov and colleagues using a transient MCAO (tMCAO) rat model. At 24 hours post-treatment, Semax produced 394 differentially expressed genes (>1.5-fold change) in subcortical tissue: 191 upregulated and 203 downregulated. Of these, 155 upregulated and 157 downregulated genes directly opposed the ischemia-reperfusion damage gene expression pattern, suggesting a system-level compensatory transcriptional response (Filippenkov et al., Genes (Basel), 2020, PMID: 32580520). Twenty-five signaling pathways were identified as significantly altered.
Research note: The use of RNA-seq transcriptome analysis in the 2020 Filippenkov study represents a methodological step change relative to earlier Semax ischemia research. Where prior studies measured single protein endpoints (BDNF, NGF), transcriptome analysis captures the full gene expression response landscape — including unexpected pathways and off-target effects. That 312 of 394 Semax-responsive genes directly opposed ischemia-reperfusion damage direction is a striking finding, but it describes a correlation between gene expression patterns, not a proven causal chain to tissue protection. Researchers interpreting these data should distinguish transcriptomic correlation from mechanistically established neuroprotection.
Protein-level validation of the transcriptome findings was published by Sudarkina and colleagues in 2021, using the same tMCAO rat model at 24 hours post-stroke. Semax increased active CREB protein (a survival and plasticity transcription factor) in the subcortical damage focus; decreased MMP-9 (a matrix metalloproteinase associated with blood-brain barrier disruption) and c-Fos (an oxidative stress response marker) in frontoparietal cortex; and decreased active JNK (a pro-apoptotic kinase) in both tissue types (Sudarkina et al., International Journal of Molecular Sciences, 2021, PMID: 34201112). These protein-level changes are mechanistically consistent with the transcriptome data and provide independent corroboration at a different analytical level.
Monoaminergic Modulation: Serotonin and Dopamine System Research
In 2006, striatal microdialysis studies in rodents demonstrated that Semax (0.15 mg/kg i.p.) increased striatal 5-HIAA (serotonin metabolite) tissue content by approximately 25% at 2 hours post-dose, with extracellular striatal 5-HIAA reaching +180% of baseline within 1–4 hours (Inozemtseva et al., Neurochemical Research, 2006, PMID: 16362768). Semax alone did not directly elevate striatal dopamine levels in these studies; instead, it potentiated amphetamine-induced dopamine release and locomotor response — a pattern consistent with D-receptor sensitization rather than direct dopamine agonism.
This monoaminergic profile distinguishes Semax from compounds that act as direct monoamine releasers or reuptake inhibitors. Its serotonergic effects appear to involve indirect modulation — possibly downstream from MC4R activation — rather than direct interaction with serotonin transporters or receptors. This distinction matters for researchers designing studies where monoamine system specificity is a variable of interest.
A 2024 study in European Journal of Pharmacology examined Semax (60 nmol/kg/day i.p.) in a chronic unpredictable stress (CUS) rat model — a validated preclinical paradigm for stress-related behavioral research. Over the study period, Semax reversed CUS-induced anhedonia (as measured by sucrose preference test in rodents), attenuated adrenal hypertrophy associated with chronic HPA axis activation, and restored hippocampal BDNF that had been suppressed by chronic stress exposure (Inozemtseva et al., European Journal of Pharmacology, 2024, PMID: 39442746). The 2024 study is the most recent controlled rodent data in the Semax literature indexed on PubMed, confirming continued research interest in this peptide.
Preclinical Research Area Key Semax Finding Primary Citation BDNF / TrkB signaling +1.4× BDNF protein; +3× exon III mRNA; +1.6× TrkB phosphorylation in rat hippocampus PMID 16996037 (2006) Ischemia transcriptomics 394 DEGs at 24 h in tMCAO rat; 312 genes opposing ischemia-reperfusion pattern PMID 32580520 (2020) Ischemia protein markers ↑CREB; ↓MMP-9; ↓c-Fos; ↓JNK phosphorylation in tMCAO rat at 24 h PMID 34201112 (2021) Serotonin modulation Striatal 5-HIAA +25% at 2 h; extracellular +180% at 1–4 h in rat microdialysis PMID 16362768 (2006) Chronic stress model Reversed CUS anhedonia; attenuated adrenal hypertrophy; restored hippocampal BDNF in rats PMID 39442746 (2024) Pharmacokinetics Membrane half-life >1 h vs ~2 min for native ACTH(4-10); 0.093%/g brain at 2 min intranasal with 80% intact PMID 15344653, 16523722 (2004, 2006) Sources: Published peer-reviewed rodent model studies. All findings are preclinical and not validated in human clinical trials.
Anti-Inflammatory Cytokine Research: Emerging Preclinical Evidence
A 2023 study published in Current Drug Therapy used a validated chronic social stress (CSS) rat model — a preclinical paradigm for studying stress-induced immune dysregulation in animal models — to evaluate Semax's effects on pro- and anti-inflammatory cytokine profiles. Semax at 100 µg/kg/day i.p. for 20 days restored plasma levels of IL-1β, IL-4, IL-6, TNF-α, and TGF-β1 that had been disrupted by chronic social stress exposure in male rats (Yasenyavskaya et al., Current Drug Therapy, 2023, DOI: 10.2174/1574885517666220831155411). This cytokine normalization pattern is consistent with findings from the ischemia transcriptome data, where Semax downregulated pro-inflammatory gene networks in the damaged subcortical tissue.
It's worth noting that the cytokine research program is less mature than the BDNF or ischemia literature — the 2023 study is among the first to directly characterize Semax's effects on specific cytokine panels in a rodent model. The mechanistic link between MC4R activation and cytokine modulation is plausible (melanocortin receptors are expressed on microglia and peripheral immune cells), but the pathway specificity has not yet been delineated in Semax-specific studies.
How Does Semax Compare to Other Neuropeptides in Preclinical Research?
Semax is not the only research neuropeptide with documented BDNF-related effects in rodent models. [INTERNAL-LINK: Selank research peptide → related neuropeptide with overlapping TrkB pathway and anxiolytic effects in rodent models] and [INTERNAL-LINK: BPC-157 research peptide → tissue repair peptide with indirect angiogenic support of neurotrophin delivery] are both studied in overlapping research contexts. What distinguishes Semax in the published literature is the combination of high-affinity receptor binding data, rapid intranasal brain penetration kinetics, and transcriptome-level ischemia evidence — three analytical levels that are rarely combined for a single research peptide.
Selank, Semax's anxiolytic counterpart from the same Moscow research group, has a stronger body of evidence in open-field and elevated plus-maze rodent models but comparatively less ischemia-specific data. [INTERNAL-LINK: Selank research article → anxiolytic neuropeptide preclinical studies] BPC-157's neuroprotective data is more mechanistically diffuse — involving VEGF-angiogenesis pathways rather than direct neurotrophin induction. [INTERNAL-LINK: BPC-157 research article → gastrointestinal and neuroprotective preclinical studies] Neither Selank nor BPC-157 has Semax's level of transcriptome-level ischemia evidence as of the current literature.View our Semax research compound.
Frequently Asked Questions About Semax Preclinical Research
What is Semax and why is it studied in preclinical neuroscience?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the ACTH(4-7) fragment, extended with a Pro-Gly-Pro tripeptide to enhance enzymatic stability. It's studied in preclinical settings because of its documented BDNF-TrkB signaling activity in rodent hippocampus, rapid intranasal CNS penetration, and mechanistic data from ischemia neuroprotection animal models.
How does Semax affect BDNF in rodent models?
In 2006, Dolotov et al. (PMID 16996037) showed that a single intranasal Semax dose (50 µg/kg) in Wistar rats elevated BDNF protein ~1.4-fold, exon III BDNF mRNA ~3-fold, and TrkB phosphorylation ~1.6-fold in hippocampal tissue within hours. The induction was anatomically selective — present in basal forebrain, absent in cerebellum — consistent with regional MC4R expression distribution.
What ischemia research has been conducted with Semax in animal models?
Semax has been studied in both permanent and transient MCAO rat models. The 2020 Filippenkov transcriptome study (PMID 32580520) identified 394 differentially expressed genes at 24 hours in tMCAO rats, with 312 directly opposing ischemia-reperfusion damage direction. Protein-level studies confirmed reduced MMP-9, c-Fos, and JNK phosphorylation alongside increased CREB activation in the same model (PMID 34201112).
What is the pharmacokinetic difference between Semax and native ACTH fragments?
Native ACTH(4-10) has a plasma half-life of approximately 2–5 minutes due to dipeptidylaminopeptidase cleavage at the Phe-Pro bond. Semax's Pro-Gly-Pro extension blocks this cleavage, extending membrane-level half-life to over one hour in rat basal forebrain preparations (PMID 15344653). Intranasal delivery achieves measurable brain concentrations within 2 minutes, with ~80% intact peptide at that timepoint (PMID 16523722).
Is Semax approved for human use?
Semax is not approved for human use by the FDA or any major international regulatory authority. Limited clinical registrations exist in Russia for specific investigational contexts, but these do not constitute global regulatory approval. All peer-reviewed mechanistic data originates from in vitro assays and controlled rodent model studies. Semax is sold exclusively for laboratory and research purposes.
Conclusion: Semax in the Preclinical Research Landscape
The Semax preclinical literature is distinctive for its mechanistic depth. From high-affinity binding kinetics and intranasal pharmacokinetics to receptor-level BDNF induction and transcriptome-level ischemia responses, the published data traces a coherent mechanistic pathway from receptor binding to molecular outcomes. That coherence — and the involvement of a dedicated research group producing layered, methodologically diverse evidence — makes Semax one of the more thoroughly characterized synthetic neuropeptides in the current preclinical literature.
At the same time, important limitations apply. The majority of this research comes from a single coordinated Russian research program, with limited independent replication by Western laboratories. The ischemia transcriptome data establishes gene expression correlations but does not prove a causal chain to tissue protection. And there are no controlled human clinical trial data to validate translation of rodent model findings to human physiology.
For researchers investigating neurotrophin signaling, ischemia neuroprotection mechanisms, or melanocortin receptor pharmacology, Semax's published preclinical profile positions it as a well-characterized experimental tool. [INTERNAL-LINK: Selank research article → companion neuropeptide with complementary preclinical profile] For researchers exploring adjacent mechanisms, the related neuropeptide [INTERNAL-LINK: Epitalon research article → telomere-associated research peptide with complementary CNS research profile] offers a distinct mechanistic entry point.View our Semax research compound.
References
- Dolotov OV, Karpenko EA, Seredenin SB, Andreeva LA, Grivennikov IA, Myasoedov NF. Semax, an Analogue of ACTH(4-7) with a Prolonged Action, Binds Specifically and Modulates the Level of BDNF in the Rat Basal Forebrain. Bioorganicheskaya Khimiya. 2004. PMID: 15344653.
- Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF. Pharmacokinetics of Intranasal Semax. Bioorganicheskaya Khimiya. 2006. PMID: 16523722.
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenin SB, Kasian AO, Grivennikov IA, Myasoedov NF. Semax and Its C-Terminal Tripeptide Activate BDNF in the Rat Hippocampus. Brain Research. 2006. PMID: 16996037.
- Dolotov OV, Inozemtseva LS, Seredenin SB, Grivennikov IA, Myasoedov NF. Semax, an Analogue of ACTH(4-10), Binds Specifically and Increases Levels of BDNF Protein in Rat Basal Forebrain. Journal of Neurochemistry. 2006. PMID: 16635254.
- Inozemtseva LS, Dolotov OV, Grivennikov IA, Myasoedov NF. Intranasal Administration of Semax and Its Metabolite Pro-Gly-Pro Affects Rat Brain Monoaminergic Systems. Neurochemical Research. 2006. PMID: 16362768.
- Glazova MV, Manchenko DM, Volodina MA, Rybalkina EY, Dolotov OV, Grivennikov IA. Semax Stimulates Brain-Derived Neurotrophic Factor (BDNF) Production and Prevents Learning and Memory Deficiencies in Neonatal Rats with Hypoxia-Ischemia. Journal of Molecular Neuroscience. 2009. PMID: 19662538.
- Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Focal Brain Ischemia in Rats. Cell and Molecular Neurobiology. 2010. PMID: 19633950.
- Filippenkov IB, Remizova JA, Salina VV, Denisova AE, Limborska SA, Myasoedov NF, Dergunova LV. Semax (ACTH(4-7)-Pro-Gly-Pro) Affects the Transcriptomic Changes Caused by Transient Focal Brain Ischemia in Rats. Genes (Basel). 2020. PMID: 32580520.
- Sudarkina OY, Filippenkov IB, Stavchansky VV, Denisova AE, Yuzhakov VV, Sevan'kaeva LE, Valieva LV, Limborska SA, Myasoedov NF, Dergunova LV. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences. 2021. PMID: 34201112.
- Inozemtseva LS, Dolotov OV, Levitskaya NG, Grivennikov IA, Myasoedov NF. Semax Produces Antidepressant-Like Effects in the Chronic Unpredictable Stress Model in Rats. European Journal of Pharmacology. 2024. PMID: 39442746.
Semax is sold exclusively for laboratory and research purposes. It is not approved for human use by the FDA or any regulatory authority. All information presented in this article is derived from published preclinical research using in vitro assays and animal models. Findings from rodent studies cannot be presumed to translate directly to human physiology. Elite Biologix does not make any claims regarding the safety or efficacy of Semax for use in humans or animals.
